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Abstract: In the ﬁ  eld of HIV management, tenofovir disoproxil fumarate (TDF) plays a pivotal 
role and has been demonstrated to be a safe and well-tolerated antiviral agent. Recent data showed 
the efﬁ  cacy of TDF in the treatment of chronically hepatitis B virus (HBV)-infected patients. 
TDF was superior to adefovir dipivoxil (ADV) in both nucleos(t)ide-naïve HBeAg-positive and 
HBeAg-negative HBV patients, and appeared to be one of the most potent antiviral agents so far. 
In addition, several reports showed that TDF was also effective in the nucleos(t)ide-experienced 
population, although conﬂ  icting results have been presented concerning patients with genotypic 
resistance to ADV. TDF seems to have a good resistance proﬁ  le as well. The rtA194T mutation 
in association with lamivudine resistance may confer resistance to TDF, although both in vivo 
and in vitro studies regarding this mutation demonstrate conﬂ  icting results. As treatment with 
TDF may be associated with nephrotoxicity, all TDF-treated patients should be monitored for 
renal function at baseline and periodically thereafter. While the relative roles of interferon vs 
nucleos(t)ide analogues (NA) as initial anti-HBV therapy remains unclear, TDF will probably 
become one of the key factors in HBV management both as ﬁ  rst-choice NA for nucleos(t)ide-
naïve patients and as rescue therapy for nucleos(t)ide-experienced patients.
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Introduction
Although effective vaccines are available, chronic hepatitis B virus (HBV) infection 
is still a serious global health problem worldwide. Currently, an estimated 350 million 
people are chronically infected, and 0.5 to 1.2 million subjects die every year due to 
long-term sequalae of chronic liver disease, such as liver cirrhosis and hepatocellular 
carcinoma.1,2
Hepatitis B has a complex natural history and causes a wide spectrum of disease. 
A chronic HBV infection is deﬁ  ned by presence of hepatitis B surface antigen (HBsAg) 
in serum for more than 6 months. The rate of progression from acute to chronic HBV 
infection is primarily determined by the age at infection, which can be up to 90% in 
the setting of perinatal transmission, but is still less than 5% for adult-acquired HBV 
infection.3,4 Figure 1 depicts the natural course of chronic HBV infection, although it 
should be recognized that not all patients go through all phases.
In patients with perinatally acquired HBV infection, the immunotolerant phase is 
the ﬁ  rst phase of infection. It is characterized by the presence of hepatitis B e antigen 
(HBeAg), a high viral load ( 20,000 IU/mL), normal serum aminotransferases, and 
minimal necroinﬂ  ammation and ﬁ  brosis on liver histology. It may last 1 to 4 decades,5 
but is usually short or absent in patients who acquire HBV infection in their late child-
hood or during adulthood.
The second phase is the immuno-clearance phase, which is characterized by the pres-
ence of HBeAg, high or ﬂ  uctuating serum HBV DNA levels, persistent or intermittent 
elevation in serum aminotransferases, and active necroinﬂ  ammation on liver histology. Infection and Drug Resistance 2009:2 14
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Spontaneous HBeAg seroconversion occurs at a rate of 8% 
to 15% per year.6 Frequently, a ﬂ  are of aminotransferases 
precedes this important event.7 However, most ﬂ  ares only 
result in transient decreases in serum HBV DNA levels without 
loss of HBeAg.7
The phase that follows HBeAg seroconversion is called the 
immune-control phase or inactive carrier state. It is character-
ized by absence of HBeAg, persistently normal aminotrans-
ferases, and low serum HBV DNA levels ( 2000 IU/mL). 
The prognosis is usually benign. After spontaneous HBeAg 
seroconversion 67% of patients will have a sustained remission 
and low risk of cirrhosis and hepatocellular carcinoma.8,9
The fourth phase, chronic HBeAg-negative chronic hepa-
titis, is characterized by absence of HBeAg, detectable serum 
HBV DNA levels ( 2000 IU/mL), elevated aminotransfer-
ases, and active necroinﬂ  ammation on liver histology. Most 
patients harbor HBV variants with mutations in the precore or 
core promoter region, which abolish or downregulate HBeAg 
production.10,11 Three major patterns can be distinguished in 
this phase: a recurrent form with exacerbations and periods 
of remission (45%), an unremitting form (36%), and an 
unremitting form with acute exacerbations (20%).12
Management issues in the treatment 
of chronic hepatitis B
Ideally, all patients with chronic HBV infection should be 
treated; yet currently approved treatment options are unable to 
eradicate HBV infection. Furthermore, they are expensive, it is 
unclear whether they are effective in maintaining viral suppres-
sion in the light of antiviral drug resistance, and only limited 
long-term data on safety is available. Therefore, it is suggested 
to treat only those patients with more active or advanced liver 
disease, and others most likely to respond. It has generally been 
accepted that patients with active viral replication (serum HBV 
DNA   2000–20,000 IU/mL) and alanine aminotransferase 
(ALT) levels greater than two times the upper limit of normal 
(ULN) or advanced ﬁ  brosis are candidates for drug therapy,13 
although it has been argued that strict adherence to these recom-
mendations would exclude a substantial proportion of patients 
with signiﬁ  cant underlying disease from treatment.14–16
With the currently approved treatment options the 
ultimate goal is to prevent the development of long-term 
sequelae of chronic liver disease. As these clinical outcomes 
arise only after decades of infection, short-term surrogate 
endpoints are needed to determine the success of hepatitis B 
treatment. As a result, permanent and complete suppression 
of viral replication (at least below 2,000 IU/mL) is the main 
goal, for persistent HBV viremia is the most important pre-
dictor of progression to liver cirrhosis, hepatic failure, and 
development of hepatocellular carcinoma.17,18 HBeAg sero-
conversion remains another important endpoint in HBeAg-
positive HBV infection, because it is usually associated with 
sustained remission and very low risk for development of 
cirrhosis and hepatocellular carcinoma.8,9
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Figure 1 The natural of history of chronic hepatitis B virus infection.
Abbreviations: HBV, chronic hepatitis B virus; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase.Infection and Drug Resistance 2009:2 15
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Antiviral therapy
Currently approved agents include two formulations of 
interferon (IFN), standard interferon alfa and pegylated 
interferon (peg-IFN), and ﬁ  ve nucleos(t)ide analogues (NA); 
lamivudine, adefovir, entecavir, telbivudine, and tenofovir. 
Efﬁ  cacy, advantages and disadvantages are summarized in 
Table 1.19–30 Although available randomized controlled trials 
show encouraging short-term results, demonstrating the 
favorable effect of these agents on intermediate end points 
as HBV DNA level, liver enzyme tests and liver histology, 
limited rigorous evidence exists demonstrating the effect of 
these therapies on important long-term clinical outcomes 
such as the development of hepatocellular carcinoma or a 
reduction in liver-related deaths.31
Interferon therapy
IFN alfa has been used since the early 1990s for the treatment 
of chronic HBV infection. It largely acts through enhance-
ment of the immunological response of the host against the 
virus, although there is also limited direct antiviral effect 
on HBV replication.32 This immunomodulatory mode of 
action is reﬂ  ected in higher rates of HBeAg and HBsAg 
seroconversion, and a more durable response once treatment 
is discontinued (sustained response) compared to treatment 
with NA.23,27,30,33 Pegylation of IFN led to improved pharma-
cokinetic and pharmacodynamic properties, and resulted in a 
slightly increased efﬁ  cacy and more convenience compared 
to standard IFN.34 Among HBeAg-positive patients, subjects 
with HBV genotype A tend to respond much better than sub-
jects with genotype non-A.23 Follow-up studies demonstrated 
that IFN had long-term beneﬁ  ts in that it promotes cumulative 
HBeAg and HBsAg seroconversion, prevention of cirrhosis 
and hepatocellular carcinoma, and prolonged survival.35,36 
However, IFN-based therapy is associated with a wide 
spectrum of adverse events, including ﬂ  u-like symptoms, 
emotional lability, and bone marrow depression. Still, only 
few patients require dose modiﬁ  cation or discontinuation of 
treatment, and symptomatic therapy fulﬁ  ls in most instances.34 
IFN is contraindicated in patients with decompensated liver 
cirrhosis, but has proven to be safe and effective in patients 
with advanced ﬁ  brosis and compensated liver disease.37
Nucleos(t)ide analogue therapy
The introduction of NA heralded a new era in the treatment of 
chronic hepatitis B, and provided a safe, effective, and well-
tolerated alternative for IFN. NA target the reverse transcriptase 
of HBV and are potent inhibitors of viral replication. Initiation 
of treatment usually results in a rapid decline of serum HBV 
DNA levels. Nevertheless, this antiviral potency does not result 
in increased HBeAg seroconversion rates (∼ 20% after 1 year of 
therapy), and HBsAg-seroconversion is very rare (Table 1).
A major drawback is that NA probably have to be admin-
istered for extremely long periods of time, if not indeﬁ  nitely. 
HBV covalently closed circular DNA (cccDNA) plays a major 
role in viral persistence.38 Yet, it is questionable whether NA 
are, in fact, able to deplete the pool of intrahepatic cccDNA 
to levels below which the immune response might be able to 
control the infection. First, none of the currently available 
NA has demonstrated to be able to prevent de novo formation 
of cccDNA in infected hepatocytes. New hepatocytes will, 
therefore, continue to be infected as long as residual circulat-
ing virions are present in the bloodstream. Second, incomplete 
inhibition of viral synthesis allows recycling of nucleocapsids 
towards the nucleus thereby maintaining the cccDNA pool.38,39 
It has been shown that adefovir (ADV) monotherapy is able 
to decrease intrahepatic cccDNA.40 Yet, based on these data 
mathematical models predicted that it would take at least 
14 years to completely clear a chronically infected liver of 
intracellular cccDNA.41 Furthermore, when ADV was com-
bined with peg-IFN, clearance of cccDNA was enhanced, and 
in contrast to ADV monotherapy, it also resulted in a strong 
reduction of HBV antigen-positive hepatocytes.42 Together 
with the increased HBeAg and HBsAg seroconversion rates 
with peg-IFN monotherapy, these ﬁ  ndings indicate that to 
eradicate HBV, modulation of the immune response, whether 
or not induced by peg-IFN, is of vital importance. In conclu-
sion, with NA therapy suppression of viral replication can 
be maintained over prolonged periods with ongoing therapy 
(maintained response), but a sustained off-treatment response 
seems only possible in a minority of patients. Current guide-
lines recommend that, in HBeAg-positive patients, treatment 
may be stopped after HBeAg seroconversion and at least 6 
months of consolidation therapy. In HBeAg-negative patients, 
discontinuation is only possible after HBsAg loss.13
Long-term treatment is associated with an increased risk for 
development of antiviral drug resistance, which can eventually 
lead to reversion of virologic and histological improvement, and 
enhance the rate of disease progression.43 Antiviral drug resis-
tance reﬂ  ects reduced susceptibility of a virus to the inhibitory 
effect of a drug. It results from a process of adaptive mutations 
under therapy. The ﬁ  rst manifestation of antiviral resistance 
is a virologic breakthrough which is deﬁ  ned as a  1 log10 
increase in serum HBV DNA from nadir during treatment in a 
patient who had an initial virologic response. It is usually also 
followed by a biochemical breakthrough. HBV has a high rate 
of replication, with 1012 virions produced per day and a high Infection and Drug Resistance 2009:2 16
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Table 1 One year efﬁ  cacy, advantages, and disadvantages of approved treatments of chronic hepatitis B
Peg-IFN Lamivudine Adefovir Entecavir Telbivudine Tenofovir
e(+)e ( −)e ( +)e ( −)e ( +)e ( −)e ( +)e ( −)e ( +)e ( −)e ( +)e ( −)
Dose/route subcutaneous oral oral oral oral oral
HBV DNA
 Log  reduction 2.4 2.3 5.4–5.8 4.2–4.5 3.6 3.7 6.9 5.0 6.5 5.2 NA NA
 Undetectablea 14% 19% 40% 73% 12%–21% 51%–59% 67% 90% 60% 88% 74% 92%
HBeAg seroconversion 32% NP 18%–22% NP 12%–18% NP 21% NP 23% NP 21% NP
HBsAg seroconversion 3.0% 2.8% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
ALT normalization 41% 59% 60%–75% 73%–79% 48%–54% 72%–78% 68% 78% 77% 74% 69% 77%
Side effects Many Negligible Nephrotoxicity Negligible Negligible Nephrotoxicity
Drug resistance
 Year  1 NA 24% 0% 0.1% 6.8% 0%
 Year  2 NA 42% 3% 0.3% 17% 0%
 Year  3 NA 53% 11% 0.4% NA NA
 Year  4 NA 70% 18% 0.8% NA NA
 Year  5 NA 74% 29% 1.2% NA NA
aUndetectable HBV DNA is deﬁ  ned as less than 400 copies/mL. Studies on entecavir and telbivudine used 300 copies/mL.
Abbreviations: ALT, alanine aminotransferase; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; NA, not applicable; NP, not possible; 
Peg-IFN, pegylated interferon.
mutational rate of approximately 10−5 substitutions/base/cycle.44 
This translates to approximately 1010–11 point mutations per 
day in individuals with active viral replication. For the HBV 
reverse transcriptase does not have a proofreading mechanism, 
mutations can arise very quickly. As a consequence, a diversity 
of viruses (quasispecies), including mutants with single and 
double mutations potentially associated with drug resistance, 
may exist prior to therapy. Furthermore, development and 
ampliﬁ  cation of mutant populations is replication-dependent, 
meaning that resistance only emerges when replication occurs 
in the presence of the drug selection pressure. Several studies 
have already shown that an initial virologic response is asso-
ciated with lower rates of antiviral drug resistance in HBV 
patients in the long term.25,45,46 Therefore, antiviral therapy, once 
initiated, should aim to suppress viral replication as quickly and 
completely as possible. To prevent the emergence of antiviral 
drug resistance only potent NA with a high genetic barrier, 
meaning drugs requiring multiple resistance mutations, should 
be used as monotherapy.
It is currently recommended to start with monotherapy 
and to use an add-on strategy in case of development of 
resistant HBV mutants.13 However, treatment strategies 
focused on preventing development of resistance by sup-
pressing viral replication as quickly and completely as 
possible, have also been advocated. The so-called roadmap 
concept, which concerns on-treatment monitoring during 
NA treatment, was recently proposed.47 In order to prevent 
future development of antiviral drug resistance, virologic 
response should be assessed at week 12 and 24 to identify 
suboptimal response and to modify treatment accordingly. 
However, it is questionable whether this concept still applies 
if potent drugs with low resistance rates are used from the 
start. Another option is to offer de novo combination of NA 
therapy. The concept of combination therapy has long been 
established as the paradigm of therapy for a number of other 
chronic infections. In the treatment of HIV, it has not only 
been proven to diminish or delay the occurrence of resistance 
due to greater potency and a higher genetic barrier, but also 
to reduce mortality.48 Nevertheless, in the light of antiviral 
agents with excellent resistance proﬁ  les, the beneﬁ  t of de 
novo combination therapy may be difﬁ  cult to demonstrate 
in HBV-monoinfected patients.
Pharmacological properties 
and mode of action of tenofovir
Tenofovir [9-(R)-(2-phosphonomethoxypropyl)adenine, 
PMPA] belongs to a class of acyclic phosphanate nucleotide 
analogues. Its antiviral activity was ﬁ  rst described in 1993, 
and, in contrast to adefovir, the antiviral activity spectrum 
of tenofovir is restricted to retroviruses and hepadnaviruses, 
and does not encompass herpesviruses.49 To increase bio-
availability by the oral route, tenofovir has been converted 
to its oral prodrug form, tenofovir disoproxil, by adding two 
alkyl methyl carbonate esters.50 Due to improved cellular 
permeability in vitro studies demonstrated a 50-fold increase 
in potency.51Infection and Drug Resistance 2009:2 17
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Upon oral administration, tenofovir disoproxil fumarate 
(TDF) is rapidly hydrolyzed after gastrointestinal absorp-
tion, which removes the two ester groups after which the 
free parent compound is released into the circulation.50,52 
Tenofovir is taken up by cells via a passive process endocy-
tosis, then phosphorylated by the cellular nucleotide kinase, 
adenylate kinase, to the monophosphate intermediate and 
then rapidly converted by nucleoside diphosphate kinase to 
the active diphosphate form.53 Tenofovir diphosphate selec-
tively inhibits the reverse transcriptase- DNA polymerase 
of HBV through competition with the natural substrate 
deoxyadenosine 5´-triphosphate for incorporation into DNA 
during HBV transcription. As tenofovir lacks a 3´-hydroxyl 
group, incorporation in DNA prevents further DNA chain 
elongation, and causes termination of viral DNA growth.54 
Tenofovir is primarily eliminated through the kidney. It is 
cleared by a combination of glomerular ﬁ  ltration and active 
secretion by the proximal tubular cells.55
Pharmacokinetics and pharmacodynamics
Dose-escalating pharmacokinetic studies have only been 
performed in HIV-infected patients. Following 28 days 
of dosing, administration of TDF once daily at all of the 
doses studied (75, 150, 300, 600 mg) resulted in signiﬁ  cant 
decreases in serum HIV-1 RNA levels, with the greatest 
effect achieved at the 300-mg dose, despite dose-propor-
tional increases in drug exposure.56 In addition, the efﬁ  cient 
phosphorylation and long intracellular half-life of tenofovir 
diphosphate ( 60 hours) indicates that a single daily dose 
of TDF is sufﬁ  cient to exert a potent antiviral effect in the 
liver, which is supported by the results of clinical pharma-
cokinetic studies.51 Furthermore, TDF can be administered 
without regard to meals, and no demographic parameters 
affect tenofovir pharmacokinetics across patients or healthy 
subjects.55 As TDF is primarily cleared through the kidney, 
dosage adjustments are required in patients with moderate 
and severe renal impairment and in those end-stage renal 
disease patients maintained on long-term hemodialysis 
(Table 3).55 No substantial alterations were observed in 
patients with moderate or severe hepatic impairment.55 TDF 
is not approved for use in children younger than 18 years 
of age. Until now, only one small uncontrolled study of 
safety and pharmacokinetics has been performed in children, 
demonstrating similar results as seen in adult patients.57 
Tenofovir is not a substrate, inducer or inhibitor of human 
cytochrome P450 enzymes, which suggests a low potential 
for clinically important drug–drug interactions with drugs 
that are substrates or inducers/inhibitors of these enzymes. 
Multiple clinical drug-interaction studies have been done 
with mainly medications that are frequently prescribed in 
HIV-1-infected subjects. With the exception of didanosine 
and atazanavir, which both require dose modiﬁ  cations; no 
clinically signiﬁ  cant drug interactions have been observed 
with TDF.55
Clinical efﬁ  cacy of tenofovir 
disoproxil fumarate
Efﬁ  cacy of TDF in patients with a HIV/HBV 
coinfection
TDF was licensed for the treatment of human immunodeﬁ  -
ciency virus (HIV) infection in 2001, and plays since then a 
pivotal role in HIV management. Currently, the combina-
tion of TDF and emtricitabine is the most widely prescribed 
nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone 
in Europe, and is being used in many clinical trials. Because 
HIV and HBV share similar routes of transmission, preva-
lence of HBsAg-carriership is more than 5-fold higher among 
HIV-infected patients compared to the general population.58,59 
As a logical consequence, the efficacy of TDF in HBV 
therapy was ﬁ  rst described in several small studies including 
mainly patients with HIV-1 co-infection, and some receiving 
combination therapy with lamivudine (LAM).60–78 In 2002 
the clinical anti-HBV efﬁ  cacy of TDF was ﬁ  rst reported by 
Nunez et al who described 12 HBV/HIV coinfected patients 
with detectable HBV DNA levels, despite receiving a LAM-
containing antiretroviral regimen. After the addition of TDF 
a drop in viral load of 3.78 log10 copies/mL after 24 weeks 
of treatment was observed.71 Larger studies conﬁ  rmed these 
early observations. Van Bommel et al compared the antiviral 
efﬁ  cacy of TDF with ADV in a mixed population of HBV 
monoinfected and HBV/HIV coinfected patients with geno-
typic evidence of LAM-resistance (n = 53). After 48 weeks 
of treatment all TDF-treated subjects achieved undetectable 
HBV DNA levels ( 400 copies/mL), whereas this endpoint 
by only 44% of ADV-treated patients was demonstrated. 
Moreover, HBeAg loss occurred in 11 (35%) of 31 HBeAg-
positive patients, and HBsAg loss was observed in 5 (14%) 
of TDF-treated patients during the study period (72–130 
weeks).77 A recently performed randomized controlled trial 
conﬁ  rmed that TDF is clearly not inferior to ADV, and thus 
demonstrated that a TDF-containing antiretroviral regimen is 
preferable for HIV/HBV coinfected patients, when treatment 
for HIV infection is indicated. The conclusion that TDF is 
superior to ADV based on this study should however be made 
with caution, as it was designed and powered to demonstrate Infection and Drug Resistance 2009:2 18
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non-inferiority.72 Benhamou et al presented a retrospective 
analysis of 65 HIV/HBV coinfected patients with detectable 
HBV DNA ( 200 copies/mL) at the start of TDF therapy. 
Most patients (95%) had previously received LAM and 
developed mutations conferring LAM-resistance (69%). 
In 52 patients who were on LAM at the initiation of TDF, 
LAM therapy was maintained throughout the study. During 
median treatment duration of 12 months HBV DNA levels 
became undetectable in 30% and 82% of HBeAg-positive 
and HBeAg-negative patients, respectively. Four (7%) of 
54 HBeAg-positive patients showed HBeAg loss, but HBsAg 
loss was observed in none of the patients.61 In a recent random-
ized clinical trial 36 HIV/HBV coinfected subjects initiating 
highly active antiretroviral therapy (HAART) were random-
ized to either LAM, TDF, or LAM-TDF as HBV-active drugs 
within HAART. After 48 weeks of treatment a TDF-containing 
treatment regimen resulted in a greater proportion of subjects 
with a viral load less than 1000 copies/mL (46% vs 92% vs 
91%; p = 0.013). HBeAg and HBsAg loss was observed in 31% 
and 9% of TDF-treated patients, respectively. No differences 
in response were seen between patients treated with TDF and 
patients treated with TDF/LAM in this short-term setting.68
Efﬁ  cacy of TDF in patients with chronic 
HBV monoinfection
The results of two international phase III clinical trials, in 
which the efﬁ  cacy of TDF is compared with ADV, have 
recently been presented (Figure 2).22,28 One study studied 
HBeAg-positive nucleos(t)ide-naïve patients, the second at 
HBeAg-negative nucleos(t)ide-naïve patients. Both trials 
used a 2:1 randomization for patients to receive either TDF 
300 mg/day or ADV 10 mg/day. Primary efﬁ  cacy was evalu-
ated at 48 weeks. The primary endpoint was the combined 
presence of HBV DNA levels below 400 copies/mL and 
histological improvement, deﬁ  ned as a  2-point reduction 
in Knodell necroinﬂ  ammatory score without worsening 
ﬁ  brosis. After 48 weeks all eligible subjects with a week 48 
biopsy were switched to open-label TDF monotherapy for 
up to an additional 8 years.
In the HBeAg-positive nucleos(t)ide-naïve study, 
266 patients with compensated liver disease were 2:1 
randomized to receive either TDF 300 mg/day or ADV 
10 mg/day.22 At the end of 48 weeks of treatment 67% of 
the TDF-treated patients achieved the primary endpoint 
versus only 12% of ADV-treated patients (p   0.001) 
(Table 2 ). A total of 76% of TDF-treated patients demon-
strated undetectable HBV DNA ( 400 copies/mL) compared 
to 13% of ADV-treated subjects (p   0.001). In addition, 
more patients in the TDF-treated group had normalization of 
ALT than in the ADV-treated groups (69% vs 54%; p = 0.02). 
HBeAg seroconversion was similar in the two treatment arms 
(21% vs 18%), but HBsAg loss occurred signiﬁ  cantly more in 
the TDF-treated group (3.2% vs 0%; p = 0.02). After week 48, 
154 (88%) of 176 TDF-treated patients continued therapy, 
which produced additional viral suppression, and HBeAg and 
HBsAg loss at week 72 and 96.79,80 Eighty-four (93%) subjects 
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Figure 2 Study design of two randomized trials comparing the efﬁ  cacy of tenofovir to adefovir in both HBeAg-positive and HBeAg-negative chronic hepatitis B patients.   At or after 
week 72 there is an option to initiate emtricitabine–tenofovir combination therapy for conﬁ  rmed HBV DNA   400 copies/mL. Current follow-up is up to 96 weeks of treatment.
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originally randomized to ADV initiated TDF at week 48, of 
whom 72 patients demonstrated HBV DNA still greater than 
400 copies/mL. By week 72, patients switched from ADV 
to TDF monotherapy showed similar rates of undetectable 
HBV DNA as those receiving continous TDF monotherapy 
(intention-to-treat [ITT] analysis: 79% vs 76%; p = 0.62).80 At 
week 96, all 12 patients suppressed on ADV remained sup-
pressed on TDF, and 82% of the other 72 patients achieved 
undetectable HBV DNA. From the total study population, 
a total of 28 patients switched to open-label emtricitabine 
(FTC)-TDF combination therapy due to persistent HBV DNA 
levels greater than 400 copies/mL.79
In the HBeAg-negative, nucleos(t)ide-naïve study, 
375 patients were randomized to receive TDF 300 mg/day 
(n = 250) or ADV 10 mg/day (n = 125).28 After 48 weeks of 
treatment 71% of TDF-treated patients achieved the primary 
endpoint and 93% demonstrated HBV DNA lower than 
400 copies/mL. Within the ADV-treated group, only 49% 
and 63% of patients achieved these endpoints, respectively 
(p   0.001) (Table 2). No signiﬁ  cant differences were 
observed between the two treatment groups concerning his-
tological improvement (72% vs 69%) and ALT normalization 
(77% vs 77%). HBsAg loss was not observed in either group. 
After week 48, 235 (94%) of 250 TDF-treated patients contin-
ued treatment, which resulted in increased viral suppression 
at week 72 and 96.81,82 One hundred and twelve (90%) sub-
jects who initially were treated with ADV switched to TDF 
monotherapy at week 48. Within this group, 35 patients had 
HBV DNA greater than 400 copies/mL just prior to switch-
ing to TDF. At week 72, 108 of 112 subjects demonstrated 
undetectable HBV DNA, and at week 96 all patients who 
were on study showed HBV DNA below 400 copies/mL (ITT 
analysis week 96: 89%). None of the patients switched to 
open-label FTC-TDF combination therapy.81,82
Efﬁ  cacy of   TDF in nucleos(t)ide-experienced 
patients with chronic HBV infection
Lamivudine
LAM was the ﬁ  rst nucleoside analogue to be approved for the 
treatment of chronic HBV infection, and remained the only 
available oral anti-HBV agent for several years. A major limi-
tation is, however, its inferior resistance proﬁ  le, which leads to 
a resistance rate of approximately 20% of patients per year.83 
As a result, LAM is no longer considered as a ﬁ  rst-line agent 
for patients with a chronic HBV monoinfection. LAM also 
demonstrates signiﬁ  cant anti-HIV activity, and is commonly 
used as part of an anti-HIV combination treatment regimen. 
Therefore, in most case series of TDF-treated HIV/HBV 
coinfected patients, subjects were LAM-experienced to 
a large extent, and often received TDF as rescue therapy 
after development of LAM-resistance. As mentioned above, 
TDF demonstrated within this patient group profound anti-
HBV activity. In a recent study, the long-term efﬁ  cacy 
and safety of TDF monotherapy in treatment-experienced 
patients with chronic HBV mono-infection was described. 
Patients with genotypic resistance to ADV at baseline were 
excluded. Of 108 patients, 93 (86%) subjects were LAM-
experienced, and in 60% of patients mutations associated 
with resistance to LAM could be detected at the begin-
ning of TDF treatment. In their analysis, both preceding 
treatment with LAM and the presence of LAM resistance 
did not affect the response to TDF monotherapy.84 These 
ﬁ  ndings were conﬁ  rmed by Manns et al who performed a 
posthoc analysis of pooled data from two randomized trials 
of TDF in HBeAg-positive and HBeAg-negative HBV 
patients. In this study, 49 patients were LAM-experienced, 
which was deﬁ  ned as prior treatment with LAM for at least 
12 weeks. In 10 patients LAM-resistant mutations were 
detected at baseline. After 48 weeks of TDF treatment 
response rates between LAM-experienced and LAM-naïve 
patients were comparable (HBV DNA   400 copies/mL: 
88% vs 86%).85
Adefovir (ADV)
ADV is a nucleotide analogue similar in structure to TDF, 
and was the second oral agent approved for the treatment of 
chronic HBV infection. As nephrotoxicity is a major side 
effect of higher doses, the prescribed dose is approximately 
30-fold lower than TDF, and probably accounts for its low 
potency in vivo.21,29 The higher potency of TDF is shown in 
3 case series in which replacement of TDF with ADV resulted 
in the reappearance of viral replication.86–88 Furthermore, 
another study demonstrated in 20 lamivudine-refractory 
HBV-infected patients with a suboptimal response to ADV 
that switching to TDF resulted in further viral suppression. 
In a median time of 3.5 months 19 of 20 patients achieved 
undetectable HBV DNA levels ( 400 copies/mL), and a 
median 3.8 log10 reduction of HBV DNA was demonstrated 
after 12 months of treatment. In addition, 4 patients lost 
HBeAg and 1 patient additionally seroconverted from HBsAg 
to anti-HBs.89 These ﬁ  ndings were conﬁ  rmed by two ran-
domized trials, in which all eligible patients randomized to 
48 weeks of ADV monotherapy were switched to open-label 
TDF monotherapy at week 48 (Table 2).79–82 Van Bommel 
et al showed in a retrospective analysis of a cohort of mainly 
treatment-experienced patients that subjects with genotypic Infection and Drug Resistance 2009:2 20
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ADV resistance at the initiation of TDF had signiﬁ  cantly 
slower decrease of HBV DNA after 12 months of treatment. 
Nevertheless, during the total observation period all patients 
with a viral load at baseline of less than 7 log10 copies/mL 
achieved undetectable HBV DNA ( 400 copies/mL).90 In 
2 patients with high baseline viremia ( 7 log10 copies/mL) 
this endpoint was only achieved after addition of LAM.91 
Similar to these results, another study showed that TDF 
monotherapy might only be effective in patients with antiviral 
treatment failure to ADV in the absence of ADV-resistant 
mutations.92 Moreover, it is interesting that in both studies 
HBV mutants harboring ADV-resistant mutations persisted 
during TDF monotherapy, which may imply a selective 
advantage for these HBV variants.91,92 However, TDF has been 
used successfully for the treatment of patients who failed con-
secutive therapy with lamivudine and lamivudine–adefovir 
combination.93 Furthermore, similar results were reported 
in a randomized clinical trial, in which the efﬁ  cacy of TDF 
monotherapy is compared to TDF/FTC combination therapy 
in patients with persistent viremia during ADV monotherapy. 
At week 48 viral replication was suppressed to levels below 
400 copies/mL in 81% of patients in both treatment arms. In 
addition, TDF monotherapy resulted in undetectable HBV 
DNA in 7 of 8 patients with genotypic resistance to ADV 
at baseline.94
Entecavir
Entecavir (ETV) has a high potency and is associated 
with minimal resistance in the long-term treatment of 
nucleos(t)ide-naïve HBV-infected patients, which both 
underscore the position of ETV for ﬁ  rst-line therapy.19,26 
However, its efﬁ  cacy is compromised by prior develop-
ment of LAM-resistance, and ETV may thus not be the best 
rescue option for LAM-experienced patients.95 Experience 
with TDF in patients previously treated with ETV is limited. 
A recent case report shows TDF to be effective in a patient 
who experienced a virologic breakthrough after develop-
ment of resistance to ETV.96 Furthermore, in 7 patients 
with a suboptimal virologic response without the presence 
of ETV-resistant mutations, switching to TDF monotherapy 
resulted in a rapid decline of viral load.97
Efﬁ  cacy of TDF in cirrhotic patients 
with chronic HBV infection
A study within seven cirrhotic patients with a HIV/HBV coin-
fection demonstrated that treatment with TDF led to profound 
suppression of viral replication, and even was able to signiﬁ  -
cantly improve markers of hepatic function. All 3 patients Infection and Drug Resistance 2009:2 21
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with decompensated liver disease recompensated, which for 
1 subject enabled removal from the liver transplant waiting 
list.69 In a posthoc analysis of pooled data from 2 randomized 
trials in HBeAg-positive and HBeAg-negative HBV patients, 
TDF produced consistent responses among cirrhotic and non-
cirrhotic patients after 48 weeks of treatment.98
Resistance proﬁ  le of TDF
Until now TDF resistance has only been described in 
2 HIV-HBV co-infected patients demonstrating the A194T 
mutation in addition to LAM-resistance.99 This study 
investigated 43 HIV/HBV coinfected patients who had 
persistently detectable HBV DNA despite  24 weeks of 
TDF/LAM combination treatment. The rtA194T mutation 
was detected 48 and 77 weeks after initiation of TDF. In 
one patient a HBV subpopulation with mutations rtM204V, 
rtL180M, and rtA194T could be detected. This coincided 
with a hepatitis ﬂ  are, although it should be noted that there 
was also an increase of his CD4+ T cell count. Nevertheless, 
HBV DNA increased from 2.6 to 4.1 log10 copies/mL as well, 
and remained at that level thereafter. The other patient pre-
sented with mutations in the HBV polymerase of rtM204V, 
rtL180M, rtV173L, and rtA194T, but there was a progressive 
decline in both HBV DNA and alanine aminotransferase 
(ALT) levels. Another study reported of 5 HBV-infected 
patients also harboring the rtA194T mutation in association 
with LAM-resistance.100 A TDF-containing salvage treatment 
regimen was started after antiviral treatment failure to LAM. 
All patients demonstrated a rapid decline in viral load, and 
4 of these achieved HBV DNA levels below 6 IU/mL. In vitro 
studies show that the rtA194T mutation alone resulted in a 
7.6-fold decrease in susceptibility, but in conjunction with 
rtM204V and rtL180M led to a more than 10-fold decrease 
in susceptibility to TDF.99 These mutations also negatively 
impacted replication competence of the HBV mutants. It 
was, however, demonstrated that viral replication could be 
restored to wild-type levels if these occurred together with 
precore or basic core promoter substitutions, as for a patient 
with chronic HBeAg-negative HBV infection.101 In contrast, 
in a study by Delaney et al the rtA194T mutation, whether 
or not in combination with LAM-resistant mutations, did not 
confer resistance to TDF in vitro.51
As mentioned above, clinical studies regarding the 
efﬁ  cacy of TDF in HBV patients with genotypic ADV 
resistance demonstrate conﬂ  icting results.91–94 In vitro stud-
ies, however, show that both rtN236T and rtA181V/T HBV 
mutants remain sensitive to TDF, and are only associated 
with small decreases in susceptibility.51,93,102–105 In addition, 
observed susceptibility shifts are smaller than for ADV, and 
together with the signiﬁ  cantly higher dose, TDF should be 
able to effectively suppress viral replication in patients with 
genotypic ADV resistance. These studies also demonstrated 
that LAM-resistant HBV mutants remain completely sensi-
tive to TDF.
In the two phase III clinical trials, direct sequencing was 
performed at baseline, and at week 48 and 96 in all TDF-treated 
patients with a viral load above 400 copies/mL.106,107 Phe-
notypic analysis was done in those subjects harboring 
conserved site changes and those experiencing virologic 
breakthrough. Ten patients showed a virologic breakthrough 
in the ﬁ  rst year of treatment; in 5 patients it was observed 
during the second year. Yet, the majority of these subjects 
had evidence of non-adherence. Furthermore, none of them 
developed conserved site changes. Overall, the occurrence of 
conserved site changes was rare. Despite this extensive resis-
tance surveillance, no evidence of TDF-resistance was shown 
so far in both nucleos(t)ide-naïve and experienced patients. In 
addition, no naturally occurring baseline polymorphisms were 
associated with a reduced virologic response to TDF.
Safety and tolerability
Recently, TDF achieved the milestone of 1.5 million patient-
years of experience. As TDF is one of the most widely pre-
scribed antiretroviral agents, information on the safety proﬁ  le 
of TDF mainly comes from its use in HIV-infected subjects. 
TDF is generally well tolerated with only few side effects. 
There have been concerns about the risk of renal toxicity with 
TDF due to an association between related compounds such 
as ADV and nephrotoxicity. A recent study demonstrated 
that the 4-year cumulative rates of renal impairment and 
arterial hypertension was 18% for both within a large cohort 
of 271 chronic hepatitis B patients treated with LAM-ADV 
combination treatment.108 Data on the risk of nephrotoxicity 
with TDF are, however, somewhat inconsistent. Several case 
Table 3 Recommendations for administration of tenofovir disiproxil 
fumarate 300 mg to patients with renal impairment
Clinical condition Administration interval
CLcr (mL/min)a
    50 Every 24 h
  30–49 Every 48 h
 10–29 Twice  weekly
ESRD requiring hemodialysis Every 7 days or after a total 
of approximately 
12 h of dialysis
aCreatinine clearance.
Abbreviation: ESRD, end stage renal disease.Infection and Drug Resistance 2009:2 22
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reports have described renal toxicity in HIV-infected persons 
receiving TDF, including renal failure and Fanconi’s syn-
drome.109–111 Within a large cohort declines in creatinine 
clearance were observed, that were signiﬁ  cantly greater in 
patients receiving a TDF-containing regimen. Yet, changes 
were only small, and did not lead to a higher discontinuation 
rate.112 The clinical relevance is therefore questionable. In 
another cohort, TDF was not associated with renal dysfunc-
tion more frequently than with other anti-HIV agents, and 
in most cases exposed to TDF, it could even be attributed 
to other causes.113 In the Tenofovir Expanded Access 
programme, which was initiated prior to commercial avail-
ability in 2001, serious renal events were reported in 0.5% 
of 10,343 patients. The percentage experiencing any graded 
serum creatinine abnormality was 2.2%. A multivariate 
analysis demonstrated that elevated serum creatinine at the 
initiation of TDF, concomitant nephrotoxic medication, and 
older age were important risk factors. The most common seri-
ous renal abnormalities observed in this population, and in 
the postmarketing safety database, were renal failure (0.3%), 
Fanconi syndrome ( 0.1%), and increased serum creatinine 
( 0.1%).114 For clinical practice, all TDF-treated patients 
should be checked for renal function at baseline and periodi-
cally thereafter. Consideration should also be given to moni-
toring serum phosphate. Other side effects of interest such 
as pancreatitis are rare, and similar incidences were reported 
compared to both patients with advanced HIV disease and 
patients treated with other antiretroviral agents.114,115 Small 
decreases in bone mineral density have been reported as well, 
but the clinical relevance is debated.116 In the phase III regis-
tration trials in HBV-monoinfected patients, TDF appeared 
to be safe and was well tolerated. The incidence and grade 
of adverse events was comparable to ADV. No increased in 
serum creatinine or creatinine clearance  50 mL/min among 
TDF-treated patients were observed.22,28
Conclusion – place in therapy
In the ﬁ  eld of HIV management, TDF plays a pivotal role 
and has demonstrated to be a safe a well-tolerated antiviral 
agent. Recent data showed that the efﬁ  cacy of the use of 
TDF in the treatment of chronically HBV-infected patients. 
TDF was superior to ADV in both nucleos(t)ide-naïve 
HBeAg-positive and HBeAg-negative HBV patients, and 
appeared to be one of the most potent antiviral agents so far. 
In addition, several reports showed that TDF was also effec-
tive in the nucleos(t)ide-experienced population, although 
conﬂ  icting results have been presented concerning patients 
with genotypic resistance to ADV. TDF seems to have a 
good resistance proﬁ  le as well. The rtA194T mutation in 
association with LAM-resistance may confer resistance to 
TDF, although both in vivo and in vitro studies regarding 
this mutation demonstrate conﬂ  icting results. As treat-
ment with TDF may be associated with nephrotoxicity, all 
TDF-treated patients should be checked for renal function 
at baseline and periodically thereafter. While the relative 
roles of interferon vs NA as initial anti-HBV therapy 
remains unclear, TDF will probably become one of the 
key factors in HBV management both as ﬁ  rst-choice NA 
for nucleos(t)ide-naïve patients and as rescue therapy for 
nucleos(t)ide-experienced patients.
TDF monotherapy appears to be sufﬁ  cient in nucleos(t)ide-
naïve patients. Whether an “add-on” strategy should also be 
applied to TDF as it is with ADV in case of development 
of resistance remains to be determined. Until now, resis-
tance to TDF has not been observed, but follow-up is still 
very short, and all viremic HBV patients were switched to 
combination therapy in an early stage, thus not allowing for 
resistance to TDF monotherapy to develop. Studies investi-
gating whether a sustained response after discontinuation of 
TDF monotherapy can be achieved are needed. However, it 
seems likely, as with the other NA, that long-term or even 
indeﬁ  nite treatment is indicated for the majority of patients. 
In addition, as recently was stated by the National Institutes 
of Health, it should be stressed that there is a signiﬁ  cant lack 
of conclusive evidence for anti-HBV therapy in general, but 
especially for NA, which demonstrates a beneﬁ  cial effect on 
overall mortality, liver-speciﬁ  c mortality, or development of 
liver cirrhosis and hepatocellular carcinoma.
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